澳洲 VUCCC P/L 公司研發第一型糖尿病新藥 即將於德國上市

一型糖尿病可吃藥治癒!?

我從網路上暫時找不到這家澳洲公司 VUCCC P/L 的網址, 倒是找到了發布這則消息之 Business Wire 網站 (把原文貼到最後給大家參考).

個人對這個"新藥"仍半信半疑... 如果後續找到相關消息, 再貼文上來.

謝謝網友 H87053 提供訊息.

----------------------------

新聞稿

VUCCC P/L高興地宣佈，該公司已向歐洲專利局遞交專利保護申請，以保護該公司針對第1型胰島素依賴型糖尿病的突破性治療藥物。

該藥的研發力量源自於4所歐洲大學（圖賓根大學、海德堡大學、曼徹斯特大學和烏普薩拉大學）的通力合作，臨床試驗歷時10年以上，受試者超過15,000例，試驗的合作單位包括德國衛生部及其他合作夥伴。

VUCCC稱，該藥可使80%以上的用藥患者獲得治癒，成功完成治療且維持無病狀態的患者可在其後24個月中不再復發。

該治療藥物的給藥需要由患者的醫生根據VUCCC專利擁有的診斷檢測結果的指引密切掌控。根據這一需求，VUCCC 將在全歐洲設立診斷參考中心，以確定患者可能的治療結果。VUCCC 另稱，該公司將設立一家集中教學中心，以便對進行中的檢測項目的標準進行掌控。

據該公司估計，長遠來看，德國衛生部每年將平均節省700億歐元。該估計值是基於現有患者的治療支出以及適用該技術的病例數。

VUCCC公司將與一家大型的製藥公司和一家全球性的連鎖實驗室簽約，進行該治療藥物的市場行銷、分銷、銷售和相關實驗室服務。該藥將於2010年在德國率先上市，隨後在其他國家上市。

根據這一 商業化計畫，VUCCC P/L將與澳洲墨爾本的P+S 商業經紀公司下屬的P+S 商業顧問公司簽訂為期2年的合約，將該藥推向市場。其他專利正在申請中。

VUCCC P/L計畫進行進一步的投資，並歡迎有意者查詢。聯絡可洽P+S 商業顧問公司, 570 Glenhuntly Road, Elsternwick, VIC, 3185, Australia diabetes@psbb.com.au.

關於VUCCC P/L

VUCCC P/L是自身免疫和代謝性疾病領域的新興翹楚。該公司的業務涉及這些領域的治療藥物和診斷檢測的商業化，為全球醫療保健服務供應業者所面臨的真實而代價高昂的疾病問題提供解決方案。

公司: VUCC PTY LTD 570 Glenhuntly Road VIC3185 Elsterwick Australien
電話: +613 95 24 9700
電子郵件: diabetes@psbb.com.au

網 址: www.psbb.com.au

VUCCC P/L德國 Eva Reuter博士，+49 (0) 177 60 58 804e.reuter@dr-reuter.eu

免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯 一具法律效力之版本。

新聞來源：中央社
訊息來源：Business Wire

-------------------------------

VUCCC P/L Announces Lodgement in Germany of Patent for Treatment of Type I Diabetes

ZURICH & MELBOURNE, Australia--(BUSINESS WIRE)--VUCCC P/L is pleased to announce that it has filed for patent protection of its ground breaking new treatment regimen for Type 1 'insulin-dependent' diabetes, through the European Patent Office.

Developed with science emanating from collaborators at 4 European universities (Tübingen University, Heidelberg University, Manchester & Uppsala Universities), it is the result of over a decade of clinical trial work in with over 15,000 patients, carried out in conjunction with the German Ministry of Health and other partners.

VUCCC states that the treatment has cured the disease in more than 80% of sufferers treated and does not suffer a relapse during the first 24 months after successfully completing the treatment has remained disease free.

The treatment regimen is closely controlled in conjunction with the patient's doctor, guided by diagnostic testing proprietary to VUCCC. This development will see VUCCC establish diagnostic reference centres across Europe, to ascertain patients' potential treatment outcomes. VUCCC also states that it will establish a centralised teaching centre, for controlling the standard of the ongoing testing program.

The company estimates there will be an average long term saving to the German Ministry of Health of EUR 70 billion per year. The estimate is based on existing costs of patient management and the number of patients treatable with this technology.

VUCCC will have an agreement in place with a major pharmaceutical company and an international laboratory network for marketing, distribution, sales and related laboratory services for the treatment. It will be launched in Germany in 2010. Release in other countries will follow.

This development represents the next step in two years of commercialisation work between VUCCC P/L and P+S Business Advisory, a division of P + S Business Brokers, of Melbourne, Australia, in bringing this technology to market. Further patents are pending.

VUCCC P/L plans further investment and would welcome enquiries from serious parties. Contact can be made with P+S Business Advisory, 570 Glenhuntly Road, Elsternwick, VIC, 3185, Australia diabetes@psbb.com.au.

About VUCCC P/L

VUCCC P/L is an emerging leader in autoimmune & metabolic diseases. The company is involved in commercialising treatments and diagnostic tests in these areas, presenting solutions to real & costly disease problems facing healthcare providers globally.
Language: English
Company: VUCC PTY LTD
570 Glenhuntly Road
VIC3185 Elsterwick
Australien
Phone: +613 95 24 9700
E-mail:

diabetes@psbb.com.au
Internet:

www.psbb.com.au

Source:
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20100303005878&newsLang=en